COVID 19 Supplemental work: HIGH THROUGHPUT BIOMARKER-BASED BIODOSIMETRY

NIH RePORTER · NIH · N01 · $1,499,726 · view on reporter.nih.gov ↗

Abstract

The company is working to develop serology assays for CoV-2 vaccine studies. The project leverages experience in developing and manufacturing high-throughput serology assays, and addresses the need for high quality CoV-2 reagents and tests that can be reproducibly manufactured at large scale. They also propose a study – in collaboration with Kaiser Permanente - to evaluate measurement of antibodies in saliva to assess immunity to SARS-CoV-2.

Key facts

NIH application ID
10260009
Project number
272201700013C-P00008-9999-2
Recipient
MESO SCALE DIAGNOSTICS, LLC
Principal Investigator
GEORGE SIGAL
Activity code
N01
Funding institute
NIH
Fiscal year
2020
Award amount
$1,499,726
Award type
Project period
2017-03-15 → 2021-05-10